AB1319 efficacy and safety of the treatment with JAK inhibitors in patients with RA. results of a case series of usual clinical practice
Abstract
Background: The JAK inhibitors, a new group of targeted synthetic DMARDs were marketed in Spain in 2018. These oral drugs are a good therapeutic alternative for patients with MTX failure. These are not biologic DMARDs and its place in clinical practice is not clear. Objectives: To identify the clinical characteristics of the patients treated with JAK inhibitors in a Rheumatology service in the South of Spain. To know the efficacy and safety of these drugs used in usual clinical practice. Methods: Setting: Rheumatology department in a 3rd level University Hospital. Design: an observational and analytical case series. From September 2018 to January 15, 2019 clinical data were collected of all patients with RA (ACR/EULAR 2010) treated with JAK inhibitors. The variables collected were demographics, clinical, related to RA, comorbidities, activity (DAS28ESR) and EULAR response. Safety variables included severe adverse events, and adverse events that caused the interruption of the treatment. The protocol was approved and conducted according to the local ethic committee regulations. The statistical analysis was done with descriptive and inferential non parametric tests. Data are shown as median (percentile 25 – percentile 75). Results: In the study period, 33 patients were treated with JAK inhibitors. Two patients were excluded of this review due to lack of an evaluation of follow-up. Data of 31 RA patients are presented. They were female (74%) with RF+, ACPA+ and erosive disease…
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.